Replimune (REPL) stock plunged 19% after the FDA rejected its RP1 melanoma treatment for the second time, citing inadequate clinical trial controls.
Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma treatment for second time, citing trial design issues despite no safety concerns.
Michael Burry buys Alibaba, JD.com, and GameStop shares while increasing put options on Nvidia and Palantir, calling Palantir wildly overvalued.
PayPal (PYPL) stock rises on Canva integration news, enabling 265M users to accept payments. Second major deal in weeks as stock attempts comeback.
AMD stock surged 6.4% Friday after TSMC reported 35% Q1 revenue growth to $35.6B, signaling strong demand ahead of AMD’s May 5 earnings report.
TLDR CoinShares reported $224 million in net inflows into digital asset products last week. Switzerland led regional inflows with $157.5 million, ahead of Germany…
TLDR Dimon says the Iran conflict could raise inflation and interest rates.…
TLDR An attacker spent about $1,800 to buy roughly 40 million MFAM…
TLDR South Korea reported 90 trillion won in crypto outflows in the…
Replimune (REPL) stock plunged 19% after the FDA rejected its RP1 melanoma treatment for the second time, citing inadequate clinical trial controls.
xAI files lawsuit against Colorado’s AI law SB 24-205, claiming it restricts chatbot speech and threatens innovation in the AI industry.
